Name: KLOW 80mg | Core Research — UK research peptide supply
Price: 60.00 GBP
Availability: InStock

Description

KLOW 80mg is a four-component lyophilised blend containing BPC-157, TB-500, GHK-Cu and KPV as one catalogue preparation with a nominal total mass of 80 mg. The current source record does not establish the per-component quantities, exact TB-500 molecular form, or finished-blend analytical results, so those details are not inferred here.

For in-vitro laboratory research only; not for human or veterinary use.

Why this is a different research question from four separate vials

A blend changes the experimental question because all four constituents are present in one preparation. Evidence for an individual component can explain why that component is researched, but the findings cannot simply be added together to claim synergy, a combined mechanism or a predictable blend outcome.

BPC-157 constituent research

Why the research spans tendons and vascular biology

Tissue-repair experiments can ask very different questions. Can cells migrate into an empty area? Do they survive a defined stress? Are they more responsive to another signalling molecule? Does a vessel relax, or do endothelial cells form new vessel-like structures? Those endpoints are connected biologically but are not interchangeable measurements. [B1, B2, B3, B4]

The studies below investigate these questions in tendon-derived cells, vascular cells, isolated tissue and animal models. Their value is the detail of the experimental response, not a general claim that BPC-157 makes every tissue heal. Separating the endpoints also explains why apparently different findings need not be contradictions.

Investigated mechanisms and study findings

Cell attachment and movement: FAK and paxillin

Fibroblasts are connective-tissue cells; their movement and attachment are important questions in tendon-cell experiments. Chang and colleagues reported greater outgrowth from rat tendon explants, increased fibroblast migration and spreading, and improved survival under hydrogen-peroxide stress. In the proliferation assay described, BPC-157 did not directly increase cell proliferation. [B1]

They also found increased phosphorylation of FAK and paxillin without increased total amounts of those proteins. These proteins participate in signalling associated with cell attachment; phosphorylation changes their signalling state. The result supports investigating an attachment-and-migration pathway rather than rewriting every observation as cell multiplication. It does not establish that a damaged human tendon recovers faster. [B1]

Responsiveness to growth hormone: receptor expression and JAK2

A later study used rat tendon fibroblasts to examine growth-hormone receptor expression. BPC-157 increased the receptor’s measured RNA and protein expression. When growth hormone was then added, the pretreated cells showed increased proliferation-related measurements and activation of JAK2, an intracellular signalling protein associated with the receptor response. [B2]

The added hormone is an essential part of this finding. It distinguishes this experiment from the earlier assay in which BPC-157 alone did not directly increase proliferation. The interpretation is that receptor availability and the presence of another signal may influence the response. It is not evidence that BPC-157 is growth hormone, directly activates that receptor, or produces the same response in people. [B2]

New-vessel formation: VEGFR2, Akt and eNOS

Angiogenesis means formation of new blood vessels. Hsieh and colleagues examined endothelial cells, a chick membrane assay and a rat hindlimb-ischemia model. They reported more vessel-like structures or vessels in the relevant assays, improved experimental blood-flow recovery, and increased VEGFR2 expression. In the cultured human endothelial cells, VEGFR2 increased without a corresponding increase in VEGF-A. [B3]

VEGFR2 is a receptor; VEGF-A is one of the signals that can act through it. The authors also observed receptor internalisation and activation of the VEGFR2–Akt–eNOS pathway. An endocytosis inhibitor reduced aspects of these responses. This connects receptor trafficking with the measured outcome, but does not by itself prove that BPC-157 binds VEGFR2 directly. Human-derived cultured cells are not a human clinical trial. [B3]

Vessel relaxation: nitric oxide and the endothelial lining

Another study asked a different question: could BPC-157 influence the tension of an already existing vessel? Isolated rat aortic rings showed relaxation that was reduced when the endothelial lining was removed or nitric-oxide signalling was inhibited. The work also linked the response to Src, caveolin-1 and eNOS, with findings consistent with altered regulation of nitric-oxide generation. [B4]

Importantly, the study found no direct relaxation in its three-dimensional vascular-smooth-muscle model. The endothelial context therefore matters. A vessel relaxing is not the same event as a new vessel forming, and neither laboratory endpoint establishes improved circulation or treatment of vascular disease in people. [B4]

Why the results should not be reduced to a single slogan

An earlier study reported no direct angiogenic effect in the cell cultures it examined, despite changes associated with angiogenesis in injured muscle and tendon in animals. The later positive endothelial-cell experiments used different systems and questions. This is a reason to compare models and methods, rather than erase the negative result or declare that either paper settles all angiogenesis research. [B5, B3]

Study	System and principal result	Interpretation to retain
Chang, 2011 [B1]	Rat tendon explants/cells: outgrowth, migration and stress-survival changes; no direct proliferation increase	Movement, survival and multiplication are different endpoints
Chang, 2014 [B2]	Rat tendon cells: increased receptor expression and response when growth hormone was added	The additional signalling condition matters
Hsieh, 2017 [B3]	Endothelial/CAM/rat ischemia models: vascular and receptor-trafficking findings	Receptor-associated signalling is not a demonstrated direct molecular target
Hsieh, 2020 [B4]	Isolated aorta and cellular models: endothelial/NO-dependent relaxation	A functional vessel response differs from angiogenesis
Brcic, 2009 [B5]	Negative direct cell-culture finding alongside in-vivo observations	The evidence is model-dependent, not uniformly positive

Some of these papers share investigators, so the number of publications should not be confused with the number of wholly independent replications. The repair-research comparison helps distinguish BPC-157 from TB-500, GHK-Cu and KPV without presenting them as substitutes.

TB-500-related constituent research

Three related materials that should not be conflated

Material in the literature	Structural distinction	What the distinction means
Thymosin beta-4	Full-length, 43-residue parent peptide	Its complete interaction surface is not present in a seven-residue fragment. [T2]
LKKTETQ	Seven-residue sequence without the added N-terminal acetyl group	This is the fragment named in several biological experiments. [T3, T4]
Ac-LKKTETQ	N-terminally acetylated seven-residue fragment	Identified in the analytical TB-500 work and studied alongside its metabolites. [T1, T5]

A shared sequence region explains why these materials are discussed together. It does not make their molecular identities, metabolism or experimental outcomes interchangeable. In particular, a study using LKKTETQ must not automatically be reported as a finding for Ac-LKKTETQ, and neither should inherit every reported activity of full-length thymosin beta-4.

Why actin biology is relevant

Actin contributes to the internal framework that enables cells to organise their shape and movement. Research on thymosin beta-4 asks how its interaction with actin influences that framework. Mutational work on the full-length peptide found contributions from both its N-terminal region and central sequence motif. The interaction therefore involves more than the isolated short sequence alone. [T2]

The short fragment is useful as a research question precisely because it removes most of the parent sequence. Comparing the relevant materials can help separate a region-associated response from a property requiring the intact parent. Describing the fragment as the complete actin-sequestering machinery would skip that distinction.

What fragment studies have actually found

Aged-animal skin-repair research

Philp and colleagues investigated full-length thymosin beta-4 in impaired skin-repair models and separately tested the unacetylated LKKTETQ fragment in aged mice. They reported a repair response with that fragment. The paper’s parent-peptide findings also varied by model: the diabetic-mouse experiment did not show an additional keratinocyte-migration difference. [T3]

Keratinocytes are epithelial skin cells. Their migration, wound contraction and collagen deposition are different measurements, so a positive result for one should not be rewritten as improvement in all three. The aged-animal fragment finding explains scientific interest; it is not evidence that this acetylated research vial heals human injuries.

Cell movement is not always increased

Shah and colleagues examined human hepatic stellate cells, which can participate in the matrix-producing response associated with liver injury. In a PDGF-BB-stimulated cell model, the LKKTETQ fragment reduced activation-related markers, collagen-related expression, proliferation and migration, alongside changes in Akt signalling. [T4]

That result points in a different direction from the simple slogan “increases cell migration”. The cell type, starting stimulus and endpoint matter. The experiment supports a model-specific interpretation of the unacetylated fragment, not a universal pro-migration effect or a treatment claim for liver disease.

The parent compound and its metabolites can behave differently

Rahaman and colleagues developed a method to quantify Ac-LKKTETQ and its metabolites, then compared them in fibroblast assays. Only the metabolite Ac-LKKTE showed a statistically significant wound-healing assay response against the control in the reported screen; the parent was not the positive material in that comparison. [T5]

This is an important qualification, not a reason to discard the study. It distinguishes what was initially present from what may appear after exposure to a biological system. The finding neither proves that the parent is inactive in every model nor establishes that a commercial vial will reproduce the metabolite response.

Recent work also tests engineered preparations

A 2025 study incorporated LKKTETQ into an enzyme-responsive peptide hydrogel. The material was designed to assemble following dephosphorylation, and the authors reported corneal-cell and barrier-related findings in their experimental systems. The tested construct was Nap-YpYY-TB500, not an unformulated Ac-LKKTETQ vial. [T6]

Delivery architecture is part of that experiment. An outcome obtained with a modified, locally retained hydrogel cannot be assigned to the free peptide simply because both descriptions use “TB500”.

GHK-Cu constituent research

Why GHK-Cu is researched

The research questions extend beyond whether a compound changes a single marker. Investigators have examined the balance between extracellular-matrix production and breakdown, the signalling that accompanies inflammatory stress, and the proteins involved in epithelial barriers. These questions connect molecular measurements with particular experimental tissues; they do not make every reported effect universal. [G2, G3, G4, G5]

A useful distinction is remodelling versus simply increasing collagen. Building matrix in a dermal-cell experiment and limiting excessive matrix deposition in an injured lung are different endpoints. Reading their models and comparators avoids the misleading idea that GHK-Cu must always push collagen in one direction. [G4, G5]

Investigated mechanisms and actual findings

Epithelial barriers, junctional proteins and STAT3

Epithelial cells form tissue surfaces. Their junctional proteins help organise the barrier between adjacent cells. Mao and colleagues studied GHK-Cu in chemically induced mouse colitis and in mouse epithelial-cell/macrophage co-cultures. They reported greater ZO-1 and occludin expression and improved scratch-assay closure compared with the impaired model. [G2]

When STAT3 was reduced experimentally, the additional closure and junction-protein responses were lost, while some anti-inflammatory activity remained. This supports investigating more than one signalling contribution. The paper also proposes SIRT1, an enzyme involved in protein regulation, as a candidate target; it does not settle a direct molecular target. These are preclinical barrier and signalling observations, not evidence that the supplied vial repairs the human intestine. [G2]

Inflammatory and oxidative-stress responses

Park and colleagues used LPS-stimulated macrophages and a mouse acute-lung-injury model. LPS is a bacterial component used to provoke inflammatory responses experimentally. The authors reported reduced reactive oxygen species and inflammatory cytokines, increased superoxide-dismutase activity, and reduced signalling through NF-κB p65 and p38 MAPK. They also observed less inflammatory-cell infiltration in the mouse lungs. [G3]

Here, cytokines are signalling molecules and reactive oxygen species are chemically reactive oxygen-containing molecules. Measuring their change helps distinguish an inflammatory response from an oxidative-stress response. The results connect several endpoints in those models; they do not demonstrate a general treatment for human lung disease. [G3]

Matrix accumulation, fibrosis and TGF-β/Smad signalling

Fibrosis involves excessive matrix deposition. Ma and colleagues examined bleomycin-induced lung fibrosis in mice and reported reduced collagen accumulation and inflammatory changes. Their measurements also implicated Nrf2-related oxidative-stress responses, NF-κB and TGF-β/Smad signalling, with changes in markers associated with epithelial-to-mesenchymal transition. [G4]

The study helps explain why researchers examine both matrix turnover and inflammatory pathways. It is not evidence of an anticancer effect, prevention of metastasis, or a universal reduction in collagen in every tissue. A pathway’s involvement in several diseases does not make a finding in one model a result for all of them. [G4]

What skin and topical studies add

Badenhorst and colleagues combined a dermal-fibroblast experiment with a separate topical-serum study. Their cell work reported changes in matrix-regulating enzymes and inhibitors alongside increased collagen and elastin production. The topical component tested a formulated nano-carrier serum, not an unformulated research vial. [G5]

In its eight-week vehicle-control comparison, the reported mean wrinkle-volume change from baseline was −24.1% for the GHK-Cu serum and −15.0% for the control serum. The often-quoted 55.8% is a separate between-treatment comparison reported by the authors, not the serum’s percentage change from baseline. The study was small and formulation-specific, and reported commercial funding. These details matter when reading cosmetic claims. [G5, Table 2 and Disclosure]

The findings are not uniformly positive across settings. In Miller and colleagues’ small study after laser resurfacing, objective wrinkle, skin-quality and redness assessments did not show a significant between-group advantage, although satisfaction favoured the GHK-Cu regimen. Different formulations, procedures and endpoints prevent treating the two studies as identical tests. [G6]

Evidence area	What it contributes	What remains specific to the study
Epithelial models [G2]	Barrier-protein and perturbation findings	Mouse systems and the experimental injury
Macrophage/lung models [G3]	Linked inflammatory and oxidative-stress observations	LPS challenge and measured pathways
Fibrosis model [G4]	Matrix-deposition and signalling observations	Bleomycin-induced mouse lung fibrosis
Topical formulation [G5]	A positive, comparator-specific cosmetic result	The tested serum and study design
Post-procedure topical regimen [G6]	Mixed objective and participant-reported findings	The laser-resurfacing setting

For comparison with other materials, the repair-research comparison explains their distinct identities. It is not a list of interchangeable substitutes.

KPV constituent research

Why KPV is researched

Two questions recur in the literature. First, how does a small peptide enter the cells involved in an inflammatory response? Second, once exposed to it, what changes occur in signalling, cytokine release or cellular injury? More recent formulation work adds a third question: how can a delivery system alter where the peptide arrives and how long it remains available? [K1, K2, K4, K5]

These are distinct questions. A transport finding is not a complete mechanism of action. A change in an inflammatory marker is not automatically restoration of tissue function. A successful carrier is not proof that the unformulated peptide behaves identically.

PepT1 uptake and inflammatory signalling

Getting into the cell

Dalmasso and colleagues investigated KPV in human intestinal epithelial-cell and T-cell models. Their uptake work, including competition and radiolabelled-peptide experiments, supported transport through PepT1, a transporter for small peptides. They also examined chemically induced colitis in mice. [K1]

PepT1 is a transport route, not simply another name for a melanocortin receptor. The study therefore provides a more specific explanation than assuming that a peptide derived from α-MSH must reproduce the parent hormone’s receptor behaviour. Nor should KPV’s small molecular weight be treated as proof of unrestricted passive entry into cells.

What changed after exposure

In the stimulated cellular systems, the authors reported reduced activation of NF-κB and MAP-kinase inflammatory signalling, alongside reduced pro-inflammatory cytokine secretion. In their mouse experiments, inflammatory outcomes and cytokine-expression measurements also changed. [K1]

NF-κB and MAP-kinase pathways help transmit signals within cells; cytokines are signalling molecules released between cells. Measuring these separately helps connect a cellular response with the surrounding inflammatory conditions. The study links uptake with those observations, but does not establish the precise direct intracellular binding target or a treatment effect in people.

Skin-cell stress research

Sung and colleagues examined KPV in human HaCaT keratinocytes exposed to fine particulate matter, with additional observations in a three-dimensional skin model. They reported improved cell-viability measurements, lower IL-1β secretion and changes in reactive oxygen species and related inflammatory/cell-death signalling. [K4]

Reactive oxygen species are chemically reactive oxygen-containing molecules. In this model, the oxidative-stress and inflammatory measurements were connected to the particular particulate challenge. They should not be turned into a general claim that KPV prevents skin ageing, protects people from pollution or makes this vial suitable for cosmetic application.

The useful research contribution is narrower: the paper examines how the tested peptide exposure changed a defined stress response in skin-cell systems, extending the research beyond intestinal models without making the two settings interchangeable.

Delivery systems can change the experimental result

Hyaluronic-acid-functionalised nanoparticles

Xiao and colleagues loaded KPV into polymeric nanoparticles functionalised with hyaluronic acid. Their work examined delivery to colonic epithelial cells and macrophages, followed by a mouse colitis experiment using a hydrogel-containing system. The HA-functionalised formulation produced better mucosal and inflammatory outcomes than the KPV-nanoparticle/hydrogel comparator without that functionalisation. [K2]

That comparator matters. This was not simply a comparison of the commercial vial against no treatment. Carrier composition, targeting and retention were part of the investigation. The study explains why formulation researchers consider delivery architecture alongside the peptide’s biological response.

Inflammation-responsive conjugates

A 2026 study by Cheng and colleagues investigated an engineered proKPV conjugate within a self-assembling delivery platform. The design used a reactive-oxygen-species-responsive component intended to release material at inflamed sites. The authors reported improved accumulation and model responses relative to free KPV in their mouse investigations. [K5]

A conjugate changes the preparation being studied. These findings are evidence about that engineered system; they do not establish the gastrointestinal stability, exposure profile or permitted use of an unformulated laboratory vial. This distinction also prevents a formulation paper’s title from becoming an unsupported product promise.

A negative finding worth retaining

Not every KPV-related experiment reports the anticipated biological activity. Songok and colleagues tested Ac-KPV-NH₂ and glycoalkylated analogues and found no antimicrobial activity under the conditions they examined, even though the modified analogues showed resistance to proteolytic enzymes. [K3]

Enzyme stability and antimicrobial activity are different outcomes. Improving one does not demonstrate the other. The result concerns those chemical forms and assays; it is not proof that every KPV preparation is inactive, but it rules out presenting “antimicrobial” as an unconditional property of every product carrying the name.

Combination evidence

No direct KLOW-specific peer-reviewed combination study is established in the current Core Research project records. The scientifically defensible interpretation is therefore component-by-component plus the explicit statement that the 80 mg four-component preparation creates a separate formulation question.

Analytical documentation for a four-component blend

A blend report should identify the product and lot and clarify how each component is distinguished within the analytical method. A single chromatographic percentage or one mass-spectrum assignment cannot be assumed to establish four-component identity, ratio or content. The current generic ≥99% and universal ESI-MS claims are therefore not carried forward without applicable blend-specific evidence.

Request batch documentation using KLOW 80mg and the lot/order identifiers where available. Use the CoA-reading guide and single-versus-blend guide for interpretation.

Storage and receiving

Follow conditions documented for the actual KLOW preparation. Do not borrow stability intervals from any one constituent or another format. At receipt, check the product, nominal total amount, vial/packaging and lot identifiers against the order.

Research-use boundary and support